EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma

Nobuhiko Yamauchi, Dai Maruyama iD

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14166 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Nobuhiko Yamauchi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T‐cell therapy has become a commercially available treatment option for relapsed or refractory (r/r) diffuse large B‐cell lymphoma (DLBCL) with two or more lines of prior therapies, and recently for high‐risk r/r DLBCL with one prior line of therapy. The successful development of CAR T‐cell therapy for multiple relapsed DLBCL has led to a boom in subsequent trials that investigated its utility in patients with other r/r B‐cell lymphoma subtypes. However, CAR T‐cell therapy is a multistep process that includes leukapheresis and manipulation which take several weeks. Therefore, patients with rapidly progressing or bulky disease may not be able to complete the therapeutic regimen involving CAR T‐cell products. This raises the question of the generalizability of the results of pivotal studies to the entire population. In this review, we summarize the development of CAR‐T cell therapy for B‐cell lymphoma and discuss strategies to further improve the clinical outcomes of this treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinHumansImmunotherapy, AdoptiveCell- and Tissue-Based TherapyAntigens, CD19Receptors, Antigen, T-Cell

Stichwörter der Autor:innen

CAR‐Tcytokine release syndromediffuse large B‐cell lymphomaimmune effector cell‐associated neurotoxicity syndromeprimary refractory

Substanzen

Receptors, Chimeric AntigenAntigens, CD19Receptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.

ORCID-Profile: Dai Maruyama

Zitieren

APA

Yamauchi, N., & Maruyama, D. (2024). Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma. European Journal of Haematology. https://doi.org/10.1111/ejh.14166

Vancouver

Yamauchi N, Maruyama D. Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma. European Journal of Haematology. 2024. doi:10.1111/ejh.14166

BibTeX
@article{Yamauchi2024,
  author = {Yamauchi, Nobuhiko and Maruyama, Dai},
  title = {Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14166}
}
Kostenlos starten →